SCHEDULE 13G/A: BlackRock Reports 4.4% Stake in USANA Health Sciences

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.4% beneficial ownership stake in USANA Health Sciences Inc. common stock as of December 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 799,296 shares of USANA Health Sciences Inc. common stock.
• This ownership represents 4.4% of the total outstanding common stock of USANA Health Sciences Inc.
• BlackRock holds sole voting power over 788,094 shares and sole dispositive power over 799,296 shares.
• The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of USANA Health Sciences Inc.
• This filing is Amendment No. 5 to the Schedule 13G, indicating previous filings have been made by BlackRock regarding its stake in USANA Health Sciences Inc.
• The beneficial ownership is attributed to various business units of BlackRock, Inc. and its subsidiaries and affiliates, with no single subsidiary owning 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine disclosure of a passive investment by a major institutional investor, indicating continued confidence in the company without suggesting any significant new developments or concerns. The stake is below 5%, which is a common threshold for passive investment.

Positives

• BlackRock's continued disclosure of its stake indicates ongoing institutional interest in USANA Health Sciences Inc.
• The stated intent of holding shares in the ordinary course of business suggests a passive, long-term investment approach, which can be a sign of stability.

Negatives

• The reported stake of 4.4% is below the 5% threshold, meaning BlackRock is not a major controlling shareholder and does not intend to influence management or corporate strategy.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a routine disclosure by BlackRock, a leading global asset manager, regarding its passive investment in USANA Health Sciences Inc. Such disclosures are standard practice for large institutional investors managing diverse portfolios across numerous public companies.

Comparison to Industry Standards

• BlackRock's 4.4% stake in USANA Health Sciences Inc. is consistent with a typical passive institutional investment, falling below the 5% threshold that would generally indicate a more active or influential position.
• Similar to other major asset managers like Vanguard or State Street, BlackRock routinely holds passive stakes in a wide array of publicly traded companies for its various funds and clients, making this a standard portfolio management disclosure.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holder's stake, confirming BlackRock's passive investment approach.
• Management: Awareness of BlackRock's continued, albeit passive, investment.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure by BlackRock, Inc. of its passive investment in USANA Health Sciences Inc. The reported 4.4% stake is below the 5% threshold, indicating no intent to influence control. There are no new financial metrics, strategic updates, or significant changes in risk factors for USANA mentioned in this filing. Therefore, based solely on this document, a 'hold' recommendation is appropriate as it provides no new information to warrant a change in investment thesis, but confirms continued institutional interest.

Keywords

BlackRock, USANA Health Sciences, Common Stock, Schedule 13G, Beneficial Ownership, Institutional Investor, Equity Investment